NCT07176546 - TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2026

Primary Completion Date

July 31, 2030

Study Completion Date

October 31, 2030

Conditions

Granulomatosis With PolyangiitisWegener'sGPA

Interventions

DRUG

Avacopan

BID dose of 30 mg TAVNEOS (3-10mg capsules)

DRUG

Placebo

BID dose of 30mg TAVNEOS-matching placebo (3-10mg capsules)

Trial Locations (2)

Hospital for Special Surgery, New York

Hackensack Meridian School of Medicine - Advanced Lung and Airway Center, Edison